Objective: To detect the concentration of MBL and MASP-2 in serum samples of patients with primary IgA nephropathy and healthy people, and to study its role in IgA nephropathy. Methods: Thirty-three patients with IgA nephropathy diagnosed by renal biopsy for the first time in the Department of Nephrology of the First Affiliated Hospital of Baotou Medical College from December 2020 to December 2021 were selected as the IgAN group, and 33 healthy volunteers who underwent physical examination in the same hospital during the same period were selected as the healthy control group. Serum MBL and MASP-2 concentrations were measured by ELISA, and the relationship between serum MBL and MASP-2 concentrations and clinical indicators and pathological parameters was analyzed. Results: The serum MBL concentration in IgAN group was higher than that in healthy control group, and there was no difference in MASP-2 concentration between the two groups. The serum MBL of IgAN patients was positively correlated with 24 hUP, LDL-C, UA and T≥1, and negatively correlated with ALB. The serum MASP-2 was positively correlated with ESR. Conclusion: Complementary MBL pathway is involved in the disease process of IgAN. The increase of serum MBL concentration in IgAN patients is related to the increase of urinary protein, the decrease of serum albumin, the abnormality of purine and lipid metabolism, and the injury of renal tubule / interstitial. High concentration of serum MBL may be an important factor in the occurrence and development of IgAN. Increased serum MASP-2 levels in IgAN patients may be associated with chronic inflammation.
WANG Yingjie
,
MI Yan
,
WANG Caili
. Role of serum mannose-binding lectin and mannose-binding lectin - associated serine protease 2 in IgA nephropathy[J]. Journal of Baotou Medical College, 2022
, 38(10)
: 45
-50
.
DOI: 10.16833/j.cnki.jbmc.2022.10.009
[1] Zhu L, Zhang H. The genetics of IgA nephropathy: an overview from China[J]. Kidney Dis (Basel), 2015,1(1):27-32.
[2] Lai KN, Tang SC, Schena FP, et al. IgA nephropathy[J].Nat Rev Dis Primers, 2016, 2:16001.
[3] Jarrick S, Lundberg S, Welander A, et al. Mortality in IgA nephropathy: a nationwide population-based cohort study[J].J Am SocNephrol, 2019, 30(5):866-876.
[4] Medjeral-Thomas NR, O'Shaughnessy MM. Complement in IgA nephropathy: the role of complement in the pathogenesis, diagnosis, and future management of IgA nephropathy[J].Adv Chronic Kidney Dis, 2020, 27(2): 111- 119.
[5] Gaya da Costa M, Poppelaars F, van Kooten C, et al. Age and sex-associated changes of complement activity and complement levels in a healthy caucasian population[J].Front Immunol, 2018, 9: 2664.
[6] Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group[J].Kidney Int, 2017, 91(5): 1014- 1021.
[7] 中国医师协会肾脏内科医师分会, 中国中西医结合学会肾脏疾病专业委员会. 中国肾性高血压管理指南2016(简版)[J]. 中华医学杂志, 2017, 97(20)1547-1555.
[8] 朱林波. MBL与FGFR4的相互作用及其对人肾系膜细胞作用的研究[D]. 沈阳:中国医科大学, 2018.
[9] Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease[J].J Am SocNephrol, 2006, 17(6): 1724- 1734.
[10] Ohsawa I, Ishii M, Ohi H, et al. Pathological scenario with the mannose-binding lectin in patients with IgA nephropathy[J].J Biomed Biotechnol, 2012, 2012:476739.
[11] Guo WY, Zhu L, Meng SJ, et al. Mannose-binding lectin levels could predict prognosis in IgA nephropathy[J].J Am SocNephrol, 2017,28(11):3175-3181.
[12] Konieczny A, Donizy P, Gołębiowski T, et al. Clinical and histopathological factors influencing IgA nephropathy outcome[J].Diagnostics (Basel), 2021, 11(10): 1764.
[13] Lu P, Li X, Zhu N, et al. Serum uric acid level is correlated with the clinical, pathological progression and prognosis of IgA nephropathy: an observational retrospective pilot-study[J].PeerJ, 2020, 8:e10130.
[14] Lee C, Park JT, Chang TI, et al. Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD[J].Nutr Metab Cardiovasc Dis, 2022, 32(2): 410- 419.
[15] Zhao YF, Zhu L, Liu LJ, et al. Measures of urinary protein and albumin in the prediction of progression of IgA nephropathy[J].Clin J Am Soc Nephrol, 2016, 11(6):947-955.
[16] 郑林花, 张颖, 宋莎莎, 等. 血清MASP2、MASP3在IgA肾病中的作用[J]. 中国免疫学杂志, 2020, 36(1)77-83.
